BACKGROUND: HER2-positive breast cancer (HER2 + BC) is clinically distinct from other subtypes, such as triple-negative or hormone receptor–positive breast cancers, due to its unique tumor microenvironment (TME) and its heterogeneous response to neoadjuvant chemotherapy (NAC). Here, ERBB2 is linked to neoplasm.